Article
Impact of Sex and Genetic Variation in Relevant Pharmacogenes on the Pharmacokinetics and Safety of Valsartan, Olmesartan and Hydrochlorothiazide.
International journal of molecular sciences - 17 Oct 2023
Soria-Chacartegui Paula, Zubiaur Pablo, Ochoa Dolores, Navares-Gómez Marcos, Abbes Houwaida, Villapalos-García Gonzalo, de Miguel Alejandro, González-Iglesias Eva, Rodríguez-Lopez Andrea, Mejía-Abril Gina, Martín-Vilchez Samuel, Luquero-Bueno Sergio, Román Manuel, Abad-Santos Francisco
Abstract excerpt
Drug combination therapy is the most common pharmacological strategy for hypertension management. No pharmacogenetic biomarkers for guiding hypertension pharmacotherapy are available to date. The study population were 64 volunteers from seven bioequivalence trials investigating formulations with valsartan, olmesartan and/or hydrochlorothiazide. Every volunteer was genotyped for 10 genetic variants in different...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.